4DMedical (ASX:4DX) Stock Based Compensation: A$0.00 Mil (TTM As of Dec. 2025)


ASX:4DX 4DMedical Ltd ASX:4DX
64 GF Score
Price A$4.25
GF Value A$1.44
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is 4DMedical Stock Based Compensation?

4DMedical ASX:4DX +4.68% 64 Stock Based Compensation is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:4DX with a GF Score™ of 64/100 and a GF Value™ of A$1.44 (Significantly Overvalued). The stock has 2 warning signs investors should review.

4DMedical's Stock Based Compensation for the six months ended in Dec. 2025 was A$0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

4DMedical Stock Based Compensation Related Terms

4DMedical Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for 4DMedical's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4DMedical Stock Based Compensation Chart

4DMedical Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Stock Based Compensation
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

4DMedical Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:4DX
64GF Score
4DMedical Ltd ASX:4DX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4DMedical Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

What does a Stock Based Compensation of A$0.00 Mil mean?
4DMedical (ASX:4DX) has a Stock Based Compensation of A$0.00 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for 4DMedical and its competitors.
Is 4DMedical's Stock Based Compensation too high?
4DMedical's current Stock Based Compensation is A$0.00 Mil. Overall, 4DMedical has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 4DMedical's Stock Based Compensation compare to ABT and SYK?
4DMedical's Stock Based Compensation of A$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for 4DMedical and its competitors. 4DMedical's current Stock Based Compensation is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4DMedical stock overvalued right now?
Based on GuruFocus' analysis, 4DMedical (ASX:4DX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$1.44, compared to a current price of A$4.25 — trading 195.1% above its estimated fair value. The current Stock Based Compensation is A$0.00 Mil. 4DMedical's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For 4DMedical (ASX:4DX), the current Stock Based Compensation is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4DMedical (ASX:4DX) Overvalued in 2026?

Based on GuruFocus' analysis, 4DMedical stock appears to be overvalued. The current stock price of A$4.25 is trading 195.1% above its estimated GF Value™ of A$1.44. GuruFocus considers 4DMedical to be Significantly Overvalued.

Key valuation signals for ASX:4DX:

  • Stock Based Compensation: A$0.00 Mil
  • GF Value™: A$1.44 vs. price of A$4.25 (195.1% above fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ASX:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4DMedical Business Description

Other Exchanges FDMDF:USAMQ7:Germany
Address 700 Swanston Street, Level 7, Melbourne Connect, Carlton, VIC, AUS, 3053
4DMedical Ltd is a company focused on medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilizes mathematical models and algorithms to convert X-ray scans into quantitative data, aiding physicians in managing patients with respiratory and lung diseases.
64GF Score

Get the complete analysis for ASX:4DX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$4.25
Price
A$1.44
GF Value